IL-15 Recombinant Protein Cat. No.: 11-386

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:E. coli
SEQUENCE:Asn 49 - Ser 162
FUSION TAG:Tag Free
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This protein carries no "tag". The protein has a calculated MW of 12.8 kDa. The protein migrates as 13 kDa under reducing (R) condition (SDS-PAGE).
psi-iconProperties
PURITY:>95% as determined by SDS-PAGE.
PREDICTED MOLECULAR WEIGHT:12.8 kDa
PHYSICAL STATE:Lyophilized
BUFFER:PBS, pH7.4
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:IL-15,Interleukin-15,MGC9721
ACCESSION NO.:AAH18149.1
OFFICIAL SYMBOL:IL15
GENE ID:3600
psi-iconBackground and References
BACKGROUND:Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.
REFERENCES:1) Grabstein KH, et al. 1994, Science 264 (5161): 965–8.
2) Malamut G, et al. 2010, J. Clin. Invest. 120 (6): 2131–43.
3) Klebanoff CA, et al. 2004, Proc. Natl. Acad. Sci. U.S.A. 101 (7): 1969–74.
4) Teague RM, et al. 2006, Nat. Med. 12 (3): 335–41.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.